News & Views
IAH Welcomes Investment
Oct 14 2009
The Biotechnology and Biological Sciences Research Council (BBSRC) and the Institute for Animal Health (IAH) have welcomed the recent announcement by the Government of over £100million investment by the
Department for Business, Innovation and Skills (BIS) in the redevelopment of the UK’s world leading animal disease research laboratories at Pirbright in Surrey.
Professor Douglas Kell, BBSRC’s Chief Executive, said: “This new funding is a major boost for animal health research in the UK and great news for the UK scientific community. This redevelopment at Pirbright will strengthen our strategic capability to protect UK livestock and other animals – including people – from devastating diseases.”
The Government’s decision follows extensive reviews of the UK’s needs for animal health research to help ensure animal welfare and contribute to global food security. The redevelopment at Pirbright will enable implementation of recommendations arising from the Anderson (http://archive.cabinetoffice.gov.uk/fmdreview/documents/fmd_2007_review_full.pdf) and Beringer (http://www.bbsrc.ac.uk/organisation/policies/reviews/operational/0804_iah_governan ce.html) reviews.
Professor Martin Shirley, IAH’s Director, said: “I am absolutely delighted by this news. It is a clear vote of confidence in the world class science carried out at IAH and recognises the increasing threats posed by animal diseases such as foot and mouth, bluetongue, and African swine fever, which could cause massive economic and social damage.”
An independent report by consultants DTZ estimated that IAH work on Bluetongue virus potentially saved the UK economy £485million and 10,000 jobs in 2008 alone.
Buyers Guide - Major producers of analytical equipment who wish to introduce and sell their products to buyers in science and industry - Over 1,000 products and services that these companys man...
View all digital editions
Jan 17 2024 Birmingham, UK
Jan 24 2024 Tokyo, Japan
Jan 29 2024 Dubai, UAE
Jan 31 2024 Tokyo, Japan
Feb 03 2024 Boston, MA, USA